(4R)-4-[2-(呋喃-2-基)乙烯基]-4-甲基-1,3-恶唑烷-2-酮 | 566938-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4R)-4-[2-(呋喃-2-基)乙烯基]-4-甲基-1,3-恶唑烷-2-酮
• 英文名称: (4R)-methyl-4-[2-(furan-2-yl)ethenyl]-1,3-oxazolidin-2-one
• 英文别名: (4R)-4-methyl-4-[2-(furan-2-yl)ethenyl]-1,3-oxazolidin-2-one；(4R)-4-[2-(Furan-2-yl)ethenyl]-4-methyl-1,3-oxazolidin-2-one
• CAS: 566938-64-5
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: MTCGCNZSHXTYLW-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R)-4-[2-(呋喃-2-基)乙烯基]-4-甲基-1,3-恶唑烷-2-酮 在 钯 氢气 、 钯 、 silica gel 作用下， 以 甲醇 为溶剂， 反应 0.67h， 以to afford the title compound (7.95 g, yield: 78%)的产率得到(4R)-4-[2-(呋喃-2-基)乙基]-4-甲基-1,3-恶唑烷-2-酮
  参考文献：
  名称：

  Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these

  摘要：

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。

  公开号：

  US20050043386A1
• 作为产物：
  描述：

  (1,3-二羟基-2-甲基-2-丙基)(2-甲基-2-丙基)氨基甲酸 在 sodium hydroxide 、 4 A molecular sieve 、 TOYOBO 、 potassium tert-butylate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 异丙醚 、 水 为溶剂， 反应 7.34h， 生成 (4R)-4-[2-(呋喃-2-基)乙烯基]-4-甲基-1,3-恶唑烷-2-酮
  参考文献：
  名称：

  Asymmetric synthesis of α,α-disubstituted α-amino alcohol derivatives

  摘要：

  We herein report an asymmetric synthesis of alpha,alpha-disubstituted alpha-amino alcohol derivatives 3, key intermediates of a novel immunomodulator, using enzymatic desymmetrization of 2-alkyl-2-tert-butoxycarbonylamino-1,3-propanediols 1a and 1b. This method makes it possible to prepare a chiral analogue of FTY720 4. These synthetic procedures allow for a broad structure variation in order to evaluate structure-activity relationships and the mechanism of action for sphingosine 1-phosphate-1 (SIP1) receptor agonist. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.10.007

文献信息

• Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
  申请人：Nishi Takahide

  公开号：US20050043386A1

  公开（公告）日：2005-02-24

  Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。
• Amino alcohol compounds
  申请人：Nishi Takahide

  公开号：US20070105933A1

  公开（公告）日：2007-05-10

  A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  本发明涉及一种用于预防哺乳动物，例如人类，需要预防风湿性关节炎和银屑病等疾病的方法，包括向哺乳动物内部给予化合物（Ia）的药物有效量，其中R1和R2均为氢; R3为氢; R4为C1-C2烷基; n为2; X为=N-D，其中D为氢、C1-C4烷基或苯基; Y为乙烯基、乙炔基、-CO-CH2或苯基; Z为乙烯基或三亚甲基; R5为未取代的C3-C10环烷基、未取代的C6-C10芳基或取代有1-3个取代基的C3-C10环烷基或C6-C10芳基，所述取代基选自卤素、低碳基、卤代低碳基和低烷氧基的群体; R6和R7均为氢。
• Amino alcohol compounds or phosphonic acid derivatives thereof
  申请人：Nishi Takahide

  公开号：US20070142335A1

  公开（公告）日：2007-06-21

  A method for the prevention or treatment of an immunology-related disease, which is not rheumatoid arthritis or psoriasis, in a mammal in need thereof which involves administering to the mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia): wherein R 1 and R 2 are each a hydrogen, R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or a C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  一种用于预防或治疗非类风湿性关节炎或牛皮癣等免疫相关疾病的方法，涉及向需要治疗的哺乳动物中投与一种化合物的药物有效量，该化合物的药物学上可接受的盐或酯，其中该化合物具有公式(Ia)：其中R1和R2均为氢，R3为氢；R4为C1-C2烷基；n为2；X为═N-D，其中D为氢、C1-C4烷基或苯基；Y为乙烯、乙炔、—CO—CH2或苯基；Z为乙烯或三亚甲基；R5为未取代的C3-C10环烷基、未取代的C6-C10芳基，或取代有1至3个卤素、低烷基、卤代低烷基和低烷氧基的C3-C10环烷基或C6-C10芳基；R6和R7均为氢。
• AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1471054B1

  公开（公告）日：2009-07-01
• Asymmetric synthesis of α,α-disubstituted α-amino alcohol derivatives
  作者：Tsuyoshi Nakamura、Takashi Tsuji、Yukiko Iio、Shojiro Miyazaki、Toshiyasu Takemoto、Takahide Nishi

  DOI：10.1016/j.tetasy.2006.10.007

  日期：2006.10

  We herein report an asymmetric synthesis of alpha,alpha-disubstituted alpha-amino alcohol derivatives 3, key intermediates of a novel immunomodulator, using enzymatic desymmetrization of 2-alkyl-2-tert-butoxycarbonylamino-1,3-propanediols 1a and 1b. This method makes it possible to prepare a chiral analogue of FTY720 4. These synthetic procedures allow for a broad structure variation in order to evaluate structure-activity relationships and the mechanism of action for sphingosine 1-phosphate-1 (SIP1) receptor agonist. (c) 2006 Elsevier Ltd. All rights reserved.